Close
What next for edaravone?

What next for edaravone?

Reading Time: 4 minutes This is blog number 21 in our ‘Symposium Blogathon’ – counting down to the 32nd International Symposium on ALS/MND. Numbers in bold green type correspond to the code in the abstract book. Click on the number to be redirected to the full abstract (the page may take a minute to load). At present, the only…

Update on clinical trials – part 2

Update on clinical trials – part 2

Reading Time: 4 minutes This is blog number 20 in our ‘Symposium Blogathon’ – counting down to the 32nd International Symposium on ALS/MND. Numbers in bold green type correspond to the code in the abstract book. Click on the number to be redirected to the full abstract (the page may take a minute to load). Clinical trials are research…

Update on clinical trials – part 1

Update on clinical trials – part 1

Reading Time: 5 minutes This is blog number 19 in our ‘Symposium Blogathon’ – counting down to the 32nd International Symposium on ALS/MND. Numbers in bold green type correspond to the code in the abstract book. Click on the number to be redirected to the full abstract (the page may take a minute to load). Clinical trials are research…

Improving clinical trial design

Improving clinical trial design

Reading Time: 4 minutes This is blog number 18 in our ‘Symposium Blogathon’ – counting down to the 32nd International Symposium on ALS/MND. Numbers in bold green type correspond to the code in the abstract book. Click on the number to be redirected to the full abstract (the page may take a minute to load). As we learn more…

Drug discovery and development

Drug discovery and development

Reading Time: 4 minutes This is blog number 17 in our ‘Symposium Blogathon’ – counting down to the 32nd International Symposium on ALS/MND. Numbers in bold green type correspond to the code in the abstract book. Click on the number to be redirected to the full abstract (the page may take a minute to load). Drug discovery can be…